11/19/2010

Neoprobe has designated Mark Pykett as its new chief development officer. Pykett was the founder of Talaris Advisors and was chief operating officer at Alseres Pharmaceuticals. Pykett will help the company in securing approval for its tracing agent Lymphoseek, as well as determine a collaborating firm for RIGScan, another tracing agent still in early development stages.

Full Story:
MedCityNews.com

Related Summaries